

Date: 21 May 2026

To

The Secretary

**BSE Limited**

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400 001

**Scrip Code: 544293**

The Secretary

**The National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1 G Block

Bandra -Kurla Complex, Bandra (East)

Mumbai- 400 051

**Scrip Symbol: SURAKSHA**

Dear Sir / Ma'am,

**Sub: Outcome of the Board meeting held today i.e. Thursday, 21 May 2026**

**Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations') as amended from time to time**

Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') as amended from time to time, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Thursday, 21 May 2026, *inter alia*, considered and approved/ noted the following:

1. Approved the audited (standalone and consolidated) financial results of the Company for the quarter and financial year ended 31 March 2026.

In terms of Regulation 33 of the SEBI Listing Regulations, we hereby enclose the following as 'Annexure 1':

- a. Audit Report on audited (standalone and consolidated) financial results for the quarter and financial year ended 31 March 2026, issued by the Statutory Auditors of the Company.
- b. Audited (standalone and consolidated) financial results for the quarter and financial year ended 31 March 2026;
- c. Statement of Assets and Liabilities as at 31 March 2026;
- d. Cash Flow Statement for the financial year ended 31 March 2026;

Further, pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, as amended, the declaration regarding unmodified opinion on the aforesaid audited (standalone and consolidated) financial results, duly signed by Ms. Ritu Mittal, Joint Managing Director & CEO and Mr. K S Ravindra, Group CFO of the Company, is enclosed herewith as 'Annexure - 2'.

The aforesaid financial results are also being made available on the Company's website at [www.surakshanet.com](http://www.surakshanet.com)

2. Recommended dividend of ₹ 0.50 (Fifty Paise) per Equity Share of face value of ₹ 2/- (INR Two) each (i.e. 25%) for the financial year 2025-26, subject to approval of the shareholders of the Company at the ensuing 21st Annual General Meeting ('AGM') of the Company.

**Suraksha Diagnostic Limited**

**CIN: L85110WB2005PLC102265**

**Reg Office:** 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,  
Kolkata-700 156, West Bengal, India

**E-mail:** investors@surakshanet.com | **Website:** www.surakshanet.com

**Phone:**(033) 6605 9750

3. Approved the Notice convening the 21st AGM of the Company for the financial year 2025-26, to be held on Wednesday, 02 September 2026 through video conferencing/ other audio-visual means ('VC/OAVM').
4. Fixed Wednesday, 26 August 2026, as the Record Date, for the purpose of determining the entitlement of the shareholders to receive dividend for the financial year ended 31 March 2026. The dividend, if approved by the shareholders at the 21st AGM, shall be paid within the statutory period prescribed under the Companies Act, 2013.
5. Approved the appointment of M/s. Suresh Surana & Associates LLP (Firm Reg no. 121750W/W-100010) as Internal Auditor of the Company for the financial year 2026-27.
6. Approved re-appointment of M/s. S Chhaparia & Associates, (Firm Registration No.: 101591), Cost and Management Accountant, as Cost Auditor for the financial year 2026-27, subject to ratification of remuneration by the shareholders at the ensuing 21st AGM of the Company.

The detailed disclosure required under Regulation 30 read with Schedule III- Para A of Part A of SEBI Listing Regulations read with SEBI Master Circular No.: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, in respect of Item No. 5 and 6 above, are enclosed herewith as 'Annexure-3'.

The meeting of the Board of Directors commenced at 2:00 p.m. (IST) and concluded at 5:30 p.m. (IST).

You are requested to kindly take the same on record.

**For Suraksha Diagnostic Limited**

---

**Mamta Jain**  
**Company Secretary & Compliance Officer**

**Encl:** As above

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Suraksha Diagnostic Limited

Report on the Audit of the Standalone Annual Financial Results

### Opinion

We have audited the accompanying standalone annual financial results of **Suraksha Diagnostic Limited** (hereinafter referred to as 'the Company') for the year ended March 31, 2026, ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

### Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

This Statement has been prepared on the basis of the standalone annual financial statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.



# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

## Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India  
Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune [www.mska.in](http://www.mska.in)

# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Other Matter:

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our Opinion is not modified in respect of the above matter.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W/W101187



Dipak Jaiswal

Partner

Membership No.: 063682

UDIN: 26063682HRLOAA3818



Place: Kolkata

Date: May 21, 2026

Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune [www.mska.in](http://www.mska.in)

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India  
(CIN : L85110WB2005PLC102265)  
Website : www.surakshanet.com

Statement of audited standalone financial results for the quarter and year ended 31 March 2026

(₹ in lakhs)

Particulars	Quarter ended			Year ended	
	31 March 2026 (Audited) (Refer Note 2)	31 December 2025 (Unaudited)	31 March 2025 (Audited) (Refer Note 2)	31 March 2026 (Audited)	31 March 2025 (Audited)
<b>Income</b>					
I Revenue from operations	7,855.59	7,558.09	6,414.51	30,067.91	24,909.54
II Other income	130.28	98.66	94.21	435.23	438.30
<b>III Total Income</b>	<b>7,985.87</b>	<b>7,656.75</b>	<b>6,508.72</b>	<b>30,503.14</b>	<b>25,347.84</b>
<b>IV Expenses</b>					
Cost of materials consumed	1,003.18	857.65	858.89	3,610.01	2,894.54
Employee benefits expenses	1,323.23	1,303.31	999.52	5,167.00	4,190.58
Finance costs	386.52	309.86	206.33	1,233.99	838.53
Depreciation and amortisation expense	1,068.56	1,010.88	865.93	3,960.15	3,472.83
Impairment loss/(gain)	29.45	85.85	80.23	46.71	218.58
Other expenses	3,119.21	2,992.44	2,493.76	11,763.77	9,346.81
<b>Total expenses (IV)</b>	<b>6,930.15</b>	<b>6,559.99</b>	<b>5,504.66</b>	<b>25,781.63</b>	<b>20,961.87</b>
<b>V Profit before tax and exceptional items (III-IV)</b>	<b>1,055.72</b>	<b>1,096.76</b>	<b>1,004.06</b>	<b>4,721.51</b>	<b>4,385.97</b>
VI Exceptional items	-	-	-	-	-
<b>VII Profit before tax (V-VI)</b>	<b>1,055.72</b>	<b>1,096.76</b>	<b>1,004.06</b>	<b>4,721.51</b>	<b>4,385.97</b>
<b>VIII Income tax expense</b>					
(i) Current tax expense	239.31	239.35	184.53	1,072.82	1,066.83
(ii) Tax pertaining to earlier period/years	-	-	(38.22)	-	(38.22)
(iii) Deferred tax expense/(credit)	145.49	43.35	57.08	242.47	13.36
<b>Total tax expense (VIII)</b>	<b>384.80</b>	<b>282.70</b>	<b>203.39</b>	<b>1,315.29</b>	<b>1,041.97</b>
<b>IX Profit for the period/year (VII-VIII)</b>	<b>670.92</b>	<b>814.06</b>	<b>800.67</b>	<b>3,406.22</b>	<b>3,344.00</b>
<b>X Other comprehensive income</b>					
(a) Items that will not be reclassified subsequently to profit or loss					
(i) Remeasurement gain/(loss) of net defined benefit plan	37.93	12.72	(8.47)	76.09	(27.25)
(ii) Income tax effect on above	(9.55)	(3.20)	2.13	(19.15)	6.86
<b>Other comprehensive income/(losses) for the period/year, net of tax</b>	<b>28.38</b>	<b>9.52</b>	<b>(6.34)</b>	<b>56.94</b>	<b>(20.39)</b>
<b>XI Total comprehensive income for the period/year</b>	<b>699.30</b>	<b>823.58</b>	<b>794.33</b>	<b>3,463.16</b>	<b>3,323.61</b>
<b>XII Paid-up equity share capital (face value - ₹ 2 per share)</b>	<b>1,041.62</b>	<b>1,041.62</b>	<b>1,041.62</b>	<b>1,041.62</b>	<b>1,041.62</b>
<b>XIII Other equity</b>				<b>23,938.04</b>	<b>20,389.60</b>
<b>XIV Earnings per equity share ( Face Value of ₹ 2 each)</b>					
- Basic (₹) (not annualised except for year end figures)	1.29	1.56	1.54	6.54	6.42
- Diluted (₹) (not annualised except for year end figures)	1.29	1.56	1.54	6.54	6.42



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India  
(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Audited Standalone Statement of Assets and Liabilities as at 31 March 2026

(₹ in lakhs)

Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
a) Property, plant and equipment	16,853.33	13,938.29
b) Capital work-in-progress	3,498.61	532.03
c) Right-of-use assets	11,394.70	7,429.02
d) Intangible assets	110.48	148.00
e) Intangible assets under development	182.58	49.34
f) Financial assets		
i) Investments	631.11	271.48
ii) Loans	2,757.17	1,387.23
iii) Other financial assets	2,115.44	4,263.66
g) Non-current tax assets (net)	406.47	161.31
h) Other non-current assets	716.75	702.61
<b>Total non-current assets (A)</b>	<b>38,666.64</b>	<b>28,882.97</b>
<b>Current assets</b>		
a) Inventories	811.56	801.65
b) Financial assets		
i) Trade receivables	2,486.18	1,505.80
ii) Cash and cash equivalents	230.45	147.54
iii) Bank balances other than cash and cash equivalents	2,293.86	1,405.31
iv) Other financial assets	68.91	252.17
c) Other current assets	456.33	314.59
<b>Total current assets (B)</b>	<b>6,347.29</b>	<b>4,427.06</b>
<b>Total Assets (A+B)</b>	<b>45,013.93</b>	<b>33,310.03</b>
<b>Equity and Liabilities</b>		
<b>Equity</b>		
a) Equity share capital	1,041.62	1,041.62
b) Other equity	23,938.04	20,389.60
<b>Total equity (A)</b>	<b>24,979.66</b>	<b>21,431.22</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
a) Financial liabilities		
i) Borrowings	13.20	287.54
ii) Lease liabilities	11,209.10	7,122.81
iii) Other financial liabilities	2,187.30	-
b) Provisions	81.85	102.22
c) Deferred tax liabilities (net)	806.71	545.09
<b>Total non-current liabilities (B)</b>	<b>14,298.16</b>	<b>8,057.66</b>
<b>Current liabilities</b>		
a) Financial liabilities		
i) Borrowings	152.98	294.98
ii) Lease liabilities	1,425.29	1,183.76
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	233.43	196.74
- Total outstanding dues other than above micro enterprises and small enterprises	1,708.91	1,202.11
iv) Other financial liabilities	1,915.97	713.25
b) Other current liabilities	284.71	217.79
c) Provisions	14.82	12.52
<b>Total current liabilities (C)</b>	<b>5,736.11</b>	<b>3,821.15</b>
<b>Total liabilities (B+C)</b>	<b>20,034.27</b>	<b>11,878.81</b>
<b>Total equity and liabilities (A+B+C)</b>	<b>45,013.93</b>	<b>33,310.03</b>



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265



# Suraksha

Clinic & Diagnostics

## Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

### Audited Standalone Statement of Cash Flow for the year ended 31 March 2026

(₹ in lakhs)

Particulars	For the Year ended 31 March 2026 (Audited)	For the Year ended 31 March 2025 (Audited)
<b>Cash flow from operating activities</b>		
Profit before tax	4,721.51	4,385.97
Adjustments for:		
Depreciation and amortisation expense	3,960.15	3,472.83
Finance costs	1,233.99	838.53
Interest on loans and deposits	(358.45)	(380.77)
Unwinding of security deposit	(36.13)	(33.40)
Loss on sale of property, plant and equipment	29.26	25.41
Impairment loss	46.71	218.58
Security deposits written off	0.65	6.65
Bad debts written off	-	26.78
Share based payment expenses	85.28	21.11
Liabilities/ provisions no longer required written back	(37.83)	(22.97)
<b>Operating profit before working capital changes</b>	<b>9,645.14</b>	<b>8,558.72</b>
<b>Changes in operating assets and liabilities</b>		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	(1,004.09)	(818.08)
Inventories	(9.91)	(136.34)
Other financial assets	28.31	(308.54)
Other current assets	(172.33)	(99.81)
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	581.32	(7.73)
Other current liabilities	66.92	47.92
Other financial liabilities	147.54	90.95
Provisions	58.02	10.36
<b>Cash generated from operations</b>	<b>9,340.92</b>	<b>7,337.45</b>
Income tax paid (net)	(1,317.99)	(1,057.65)
<b>Net cash flows generated from operating activities (A)</b>	<b>8,022.93</b>	<b>6,279.80</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant & equipment, other intangible assets and Intangible Asset under Development (including capital work-in-progress, capital advances and capital	(5,011.79)	(3,538.85)
Proceeds from sale of property, plant & equipment	9.42	14.95
Net Redemption in deposits with banks	1,248.73	174.16
Investment in Subsidiaries	(359.63)	(155.74)
Loan given to Subsidiaries	(1,218.16)	(748.32)
Interest received on bank deposits	206.67	325.40
<b>Net cash flows used in investing activities (B)</b>	<b>(5,124.76)</b>	<b>(3,928.40)</b>
<b>Cash flow from financing activities</b>		
Repayment of borrowings	(416.34)	(281.14)
Payment of lease liabilities	(2,371.68)	(2,069.99)
Finance cost paid	(27.24)	(63.67)
<b>Net cash flows used in financing activities (C)</b>	<b>(2,815.26)</b>	<b>(2,414.80)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>82.91</b>	<b>(63.40)</b>
Cash and cash equivalents at the beginning of the year	147.54	210.94
<b>Cash and cash equivalents at the end of the year</b>	<b>230.45</b>	<b>147.54</b>



## Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

## Notes to the audited standalone financial results

1. The audited standalone financial results for the quarter and year ended 31 March 2026 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. The figures of the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended 31 December 2025 and 31 December 2024 respectively, which were subjected to limited review by the statutory auditors.
3. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 21 May 2026. These financial results for the year ended 31 March 2026 have been audited by the statutory auditor and they have issued an unmodified opinion.
4. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 --'Operating Segments'.
5. The Government of India had announced the implementation of the four Labour Codes - The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020 and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as 'the New Labour Codes') with effect from 21 November 2025.  
On 8 May 2026, the Ministry of Labour & Employment notified the final Central Rules under these Codes. The Company has assessed the impact of these changes, including the notified Rules, based on available information and actuarial valuation, and concluded that the impact accounted is not material to these standalone financial results. The Company continues to monitor the notification of State Rules.
6. The Board of Directors at its meeting held on 21 May 2026, proposed a dividend of ₹ 0.50 per equity share for FY2025-26 (FY 2024-25 ₹ Nil per equity).
7. In a step-down subsidiary of the Company, a dispute with the Government of Meghalaya (the public partner) has resulted in operational losses. As a result, the recoverability of the Company's investments and loans advanced to subsidiary & trade receivables from step-down subsidiary, aggregating to ₹ 392.20 lakhs as at 31 March 2026 is under assessment. The Management is in the process of filing a fresh arbitration through its subsidiary and the Company believes that the outcome will be in their favour. Accordingly, no provision has been considered necessary in respect of the aforesaid matter.
8. The Company has completed the acquisition of Fetomat Wellness Private Limited ('Fetomat') on April 08, 2025 by acquisition of 3,73,423 equity shares of equity shares of ₹ 10/- each representing 63% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Company.
9. These audited standalone financial results are also available on the Company's website ([www.surakshanet.com](http://www.surakshanet.com)) and on the stock exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).
10. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of  
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee  
Chairman & Joint Managing Director  
DIN: 00137075

Place: Kolkata  
Date: 21 May 2026

## Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

**INDEPENDENT AUDITOR'S REPORT**

To the Board of Directors of Suraksha Diagnostic Limited

Report on the Audit of the Consolidated Annual Financial Results

**Opinion**

We have audited the accompanying consolidated annual financial results of Suraksha Diagnostic Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2026, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid Statement:

(i) includes the annual financial results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Suraksha Radiology Private Limited	Subsidiary Company
3	Suraksha Advanced Radiology Private Limited	Subsidiary Company
4	Asian Institute of Immunology and Rheumatology LLP	Subsidiary
5	Fetomat Wellness Private Limited	Subsidiary Company
6	Suraksha Salvia LLP	Step-down subsidiary

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the consolidated net profit, consolidated other comprehensive income and other financial information of the Group, for the year ended March 31, 2026.



# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

## Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated annual financial results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below is sufficient and appropriate to provide a basis for our opinion.

## Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

This Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies/ management of the companies/ entities included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies/ management of the companies/entities included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/ management either intends to liquidate the company/entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies/ management of the companies/ entities included in the Group are responsible for overseeing the financial reporting process of each company/ entity.



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune [www.mskain.com](http://www.mskain.com)

# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

## Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements/ financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune [www.mska.in](http://www.mska.in)

# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

## Other Matters:

The Statement includes the audited financial statements of six (5) subsidiaries, whose financial statements reflect total assets of Rs. 3,368.21 lakhs as at March 31, 2026, total revenue of Rs. 1,246.88 lakhs, net loss after tax of Rs. 205.33 lakhs, total comprehensive income of Rs. (205.77) lakhs and net cash outflow of Rs. 107.01 lakhs as considered in the Statement, which have been audited by the other auditors. The other auditors' reports on the financial statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

The Statement includes the unaudited financial statements of 1 step-down subsidiary whose financial statements reflect total assets of Rs.29.50 lakhs as at March 31, 2026, total revenue of Rs. Nil, net loss after tax of Rs. 60.14 lakhs, total comprehensive income of Rs. (60.14) lakhs, and net cash outflow of Rs. 2.41 lakhs for the year ended on that date respectively, as considered in the Statement. These unaudited financial statements have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this step-down subsidiary is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune [www.mska.in](http://www.mska.in)

# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

The Statement includes the results for the quarter ended March 31, 2026, being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026, and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W/W101187



Dipak Jaiswal  
Partner



Membership No.: 063682

UDIN: 26063682YMSFEI7461

Place: Kolkata

Date: May 21, 2026

**Suraksha Diagnostic Limited**

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India  
(CIN : L85110WB2005PLC102265)  
Website : www.surakshanet.com

**Statement of audited consolidated financial result for the quarter and year ended 31 March 2026**

(₹ in lakhs)

Particulars	Quarter ended			Year ended	
	31 March 2026 (Audited) (Refer Note 2)	31 December 2025 (Unaudited)	31 March 2025 (Audited) (Refer Note 2)	31 March 2026 (Audited)	31 March 2025 (Audited)
<b>Income</b>					
I Revenue from operations	8,141.15	7,768.73	6,509.47	31,041.41	25,209.27
II Other income	78.54	62.16	81.68	316.41	384.60
<b>III Total Income</b>	<b>8,219.69</b>	<b>7,830.89</b>	<b>6,591.15</b>	<b>31,357.82</b>	<b>25,593.87</b>
<b>IV Expenses</b>					
Cost of materials consumed	1,015.79	866.62	884.80	3,647.54	2,951.91
Employee benefits expenses	1,367.02	1,341.86	1,020.34	5,325.51	4,289.03
Finance costs	391.57	315.69	206.33	1,255.33	838.53
Depreciation and amortisation expense	1,125.81	1,056.46	872.88	4,144.83	3,529.77
Impairment loss/(gain)	29.45	85.85	80.23	46.71	218.58
Other expenses	3,291.96	3,158.38	2,605.32	12,482.22	9,625.52
<b>Total expenses (IV)</b>	<b>7,221.60</b>	<b>6,824.86</b>	<b>5,669.90</b>	<b>26,902.14</b>	<b>21,453.34</b>
<b>V Profit before tax and exceptional items (III-IV)</b>	<b>998.09</b>	<b>1,006.03</b>	<b>921.25</b>	<b>4,455.68</b>	<b>4,140.53</b>
VI Exceptional items	-	-	-	-	-
<b>VII Profit before tax (V-VI)</b>	<b>998.09</b>	<b>1,006.03</b>	<b>921.25</b>	<b>4,455.68</b>	<b>4,140.53</b>
<b>VIII Income tax expense</b>					
(i) Current tax expense	241.36	238.68	185.30	1,077.69	1,067.60
(ii) Tax pertaining to earlier years	-	(0.05)	(38.22)	(0.05)	(38.22)
(iii) Deferred tax expense/(credit)	140.81	43.35	57.08	237.79	13.36
<b>Total tax expense (VIII)</b>	<b>382.17</b>	<b>281.98</b>	<b>204.16</b>	<b>1,315.43</b>	<b>1,042.74</b>
<b>IX Profit for the period/year (VII-VIII)</b>	<b>615.92</b>	<b>724.05</b>	<b>717.09</b>	<b>3,140.25</b>	<b>3,097.79</b>
<b>X Other comprehensive income</b>					
(a) Items that will not be reclassified subsequently to profit or loss					
(i) Remeasurement gain/(loss) of net defined benefit plan	37.93	12.72	(8.47)	76.09	(27.25)
(ii) Income tax effect on above	(9.55)	(3.20)	2.13	(19.15)	6.86
<b>Other comprehensive income/(losses) for the period/year, net of tax</b>	<b>28.38</b>	<b>9.52</b>	<b>(6.34)</b>	<b>56.94</b>	<b>(20.39)</b>
<b>XI Total comprehensive income for the period/year</b>	<b>644.30</b>	<b>733.57</b>	<b>710.75</b>	<b>3,197.19</b>	<b>3,077.40</b>
<b>XII Profit for the period/year attributable to</b>					
Owners of the parent	628.04	752.29	738.87	3,218.71	3,182.41
Non- controlling interests	(12.12)	(28.24)	(21.78)	(78.46)	(84.62)
	615.92	724.05	717.09	3,140.25	3,097.79
<b>XIII Other comprehensive income for the period/year attributable to</b>					
Owners of the parent	28.38	9.52	(6.34)	56.94	(20.39)
Non- controlling interests	-	-	-	-	-
	28.38	9.52	(6.34)	56.94	(20.39)
<b>XIV Total comprehensive income for the period/year attributable to</b>					
Owners of the parent	656.42	761.81	732.53	3,275.65	3,162.02
Non- controlling interests	(12.12)	(28.24)	(21.78)	(78.46)	(84.62)
	644.30	733.57	710.75	3,197.19	3,077.40
<b>XV Paid-up equity share capital (face value - ₹ 2 per share)</b>	<b>1041.62</b>	<b>1,041.62</b>	<b>1,041.62</b>	<b>1,041.62</b>	<b>1,041.62</b>
<b>XVI Other equity (including non-controlling interest)</b>				<b>23,443.28</b>	<b>20,082.35</b>
<b>XVII Earnings per equity share (Face Value of ₹ 2 each)</b>					
- Basic (₹) (not annualised except for year end figures)	1.21	1.44	1.42	6.18	5.97
- Diluted (₹) (not annualised except for year end figures)	1.21	1.44	1.42	6.18	5.97



**Suraksha Diagnostic Limited**

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

**Suraksha Diagnostic Limited**

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Audited Consolidated Statement of Assets and Liabilities as at 31 March 2026

(₹ in lakhs)

Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
a) Property, plant and equipment	19,357.85	14,713.71
b) Capital work-in-progress	3,511.63	1,009.93
c) Right-of-use assets	11,605.51	7,429.02
d) Goodwill	388.01	-
e) Intangible assets	112.16	150.00
f) Intangible Assets under Development	182.58	49.34
g) Financial assets		
i) Investments	-	100.00
ii) Other financial assets	2,161.86	4,269.13
h) Non-current tax assets (net)	419.72	162.75
i) Other non-current assets	814.66	753.26
<b>Total non-current assets (A)</b>	<b>38,553.98</b>	<b>28,637.14</b>
<b>Current assets</b>		
a) Inventories	814.31	804.89
b) Financial assets		
i) Trade receivables	2,275.77	1,381.23
ii) Cash and cash equivalents	321.41	224.68
iii) Bank balances other than cash and cash equivalents	2,313.43	1,785.89
iv) Other financial assets	68.91	253.02
c) Other current assets	463.83	265.57
<b>Total current assets (B)</b>	<b>6,257.66</b>	<b>4,715.28</b>
<b>Total Assets (A+B)</b>	<b>44,811.64</b>	<b>33,352.42</b>
<b>Equity and Liabilities</b>		
<b>Equity</b>		
a) Equity share capital	1,041.62	1,041.62
b) Other equity	23,443.28	20,082.35
c) Equity attributable to owners of the parent (a+b)	24,484.90	21,123.97
d) Non Controlling interest	(137.18)	(100.86)
<b>Total equity (A)</b>	<b>24,347.72</b>	<b>21,023.11</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
a) Financial liabilities		
i) Borrowings	17.76	287.54
ii) Lease liabilities	11,411.32	7,122.79
iii) Other financial liabilities	2,187.30	-
b) Provisions	82.55	102.22
c) Deferred tax liabilities (net)	800.05	545.09
<b>Total non-current liabilities (B)</b>	<b>14,498.98</b>	<b>8,057.64</b>
<b>Current liabilities</b>		
a) Financial liabilities		
i) Borrowings	155.68	294.98
ii) Lease liabilities	1,449.35	1,183.76
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	233.43	196.74
- Total outstanding dues other than above micro enterprises and small enterprises	1,852.75	1,167.61
iv) Other financial liabilities	1,928.37	1,077.25
b) Other current liabilities	330.54	338.04
c) Provisions	14.82	12.52
d) Current tax liabilities (net)	-	0.77
<b>Total current liabilities (C)</b>	<b>5,964.94</b>	<b>4,271.67</b>
<b>Total liabilities (B+C)</b>	<b>20,463.92</b>	<b>12,329.31</b>
<b>Total equity and liabilities (A+B+C)</b>	<b>44,811.64</b>	<b>33,352.42</b>



**Suraksha Diagnostic Limited**

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265



# Suraksha

## Clinic & Diagnostics

Suraksha Diagnostic Limited  
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India  
(CIN : L85110WB2005PLC102265)  
Website : www.surakshanet.com

Audited Consolidated Statement of Cash Flows for the year ended 31 March 2026

(₹ in lakhs)

Particulars	For the Year ended 31 March 2026 (Audited)	For the Year ended 31 March 2025 (Audited)
<b>Cash flow from operating activities</b>		
Profit before tax	4,455.68	4,140.53
Adjustments for:		
Depreciation and amortisation expenses	4,144.83	3,529.77
Finance costs	1,255.33	838.53
Interest on loans, deposits and IT refund	(225.62)	(324.52)
Unwinding of security deposit	(36.13)	(33.40)
Loss on sale of property, plant and equipment	29.26	25.58
Impairment loss	46.71	218.58
Security deposits written off	-	6.65
Bad debts written off	0.65	26.78
Share based payment expenses	85.28	21.12
Liabilities/ provisions no longer required written back	(38.13)	(22.97)
<b>Operating profit before working capital changes</b>	<b>9,717.86</b>	<b>8,426.65</b>
<b>Changes in operating assets and liabilities</b>		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	(917.27)	(721.22)
Inventories	(8.27)	(137.06)
Other financial assets	(6.89)	(309.41)
Other assets	(198.26)	(78.22)
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	743.00	(51.93)
Other liabilities	(22.48)	163.42
Other financial liabilities	152.33	91.48
Provisions	58.72	10.36
<b>Cash generated from operations</b>	<b>9,518.74</b>	<b>7,394.07</b>
Income tax paid (net)	(1,335.84)	(1,058.16)
<b>Net cash flows generated from operating activities (A)</b>	<b>8,182.90</b>	<b>6,335.91</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant & equipment, other intangible assets and intangible asset under development (including capital work-in-progress, capital advances and capital creditors)	(6,734.45)	(4,202.40)
Proceeds from sale of property, plant & equipment	9.46	14.10
Net Redemption/(Investments) in deposits with banks	1,573.66	(26.03)
Acquisition of Subsidiary, net of cash acquired	(327.10)	(100.00)
Interest received on bank deposits	261.48	355.92
<b>Net cash flows used in investing activities (B)</b>	<b>(5,216.95)</b>	<b>(3,958.41)</b>
<b>Cash flow from financing activities</b>		
Contribution from non-controlling interests	-	10.00
Proceeds of borrowings	7.73	-
Repayment of borrowings	(436.76)	(281.14)
Payment of lease liabilities	(2,411.69)	(2,070.01)
Finance cost paid	(28.50)	(63.67)
<b>Net cash flows used in financing activities (C)</b>	<b>(2,869.22)</b>	<b>(2,404.82)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>96.73</b>	<b>(27.32)</b>
Cash and cash equivalents at the beginning of the year	224.68	252.00
<b>Cash and cash equivalents at the end of the year</b>	<b>321.41</b>	<b>224.68</b>



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

## Notes to the audited consolidated financial results

1. The Audited consolidated financial results for the quarter and year ended 31 March 2026 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as 'the group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
2. The figures of the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended 31 December 2025 and 31 December 2024 respectively, which were subjected to limited review by the statutory auditors.
3. These audited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 21 May 2026. These financial results for the year ended 31 March 2026 have been audited by the statutory auditor and they have issued an unmodified opinion.
4. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.
5. The Government of India had announced the implementation of the four Labour Codes - The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020 and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as 'the New Labour Codes') with effect from 21 November 2025.  
On 8 May 2026, the Ministry of Labour & Employment notified the final Central Rules under these Codes. The Group has assessed the impact of these changes, including the notified Rules, based on available information and actuarial valuation, and concluded that the impact accounted is not material to these consolidated financial results. The Group continues to monitor the notification of State Rules.
6. The Board of Directors of Holding company at its meeting held on 21 May 2026, proposed a dividend of ₹ 0.50 per equity share for FY2025-26 (FY 2024-25 ₹ Nil per equity).
7. These Audited consolidated financial results are also available on the Holding Company's website ([www.surakshanet.com](http://www.surakshanet.com)) and on the stock exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseinda.com](http://www.nseinda.com)).
8. The Holding company has completed the acquisition of Fetomat wellness Private Limited ("Fetomat") on April 08, 2025 by acquisition of 3,73,423 equity shares of equity shares of ₹ 10/- each representing 63% of the total equity share capital of Fetomat, resulting in Fetomat becoming subsidiary of the company. As per Ind AS 103 Business combinations, the transactions has been accounted for and the difference between the consideration paid on acquisitions and fair value of net identifiable assets acquired attributed to the Holding company has been accounted for as Goodwill as on the date of acquisition.
9. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of  
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee  
Chairman & Joint Managing Director  
DIN: 00137075

Place: Kolkata  
Date: 21 May 2026

## Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Annexure-2

Date: 21 May 2026

To

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293	The Secretary The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1 G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol: SURAKSHA
---	--

Dear Sir / Ma'am,

**Sub: Declaration pursuant to the provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as amended from time to time**

Pursuant to the third proviso to Regulation 33(3)(d) of the Listing Regulations, we hereby declare and confirm that the Statutory Auditors of the Company, M/s M S K A & Associates LLP (Firm's Registration No.: 105047W/W101187), Chartered Accountants, have issued the Auditors' Report on the audited (standalone and consolidated) financial results of the Company for the quarter and financial year ended on 31 March 2026, **with unmodified opinion.**

Kindly take the above declaration on record.

For Suraksha Diagnostic Limited



Ritu Mittal  
Joint Managing Director & CEO  
DIN: 00165886

For Suraksha Diagnostic Limited



K S Ravindra  
Group Chief Financial Officer

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Annexure- 3

Details as required under Regulation 30 read with Schedule III- Para A of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No.: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026:

Particulars	Internal Auditor	Cost Auditor
<b>Name of Auditors</b>	M/s. Suresh Surana & Associates LLP (Firm Registration No.: 121750W/W-100010)	M/s. S Chhaparia & Associates, (Firm Registration No.: 101591)
<b>Reason for change viz. appointment/ re-appointment/ resignation/ removal/ death/ or otherwise;</b>	Appointment	Re-appointment
<b>Date of appointment/re-appointment/cessation (as applicable) &amp; term of appointment/re-appointment;</b>	Appointed by the Board of Directors on 21 May 2026 to conduct the internal audit of the Company for the financial year 2026-27, on such terms and conditions as may be mutually agreed between the Company and the Auditor.	Re-appointed by the Board of Directors on 21 May 2026 to conduct the audit of the cost records of the Company for the financial year 2026-27, subject to ratification of remuneration by the shareholders at the ensuing AGM and on such terms and conditions as may be mutually agreed between the Company and the Auditor.
<b>Brief profile (in case of appointment)</b>	M/s. Suresh Surana & Associates LLP is a leading audit firm in India and is a part of RSM India. They offer a range of services including internal audit, statutory audit and consulting etc.	M/s S Chhaparia & Associate, a Kolkata based firm has almost over 14 years of experience in the fields of cost audits, cost compliances, cost record maintenance, cost consultancy services, corporate law, company formation and taxation. The firm handles GST matters covering a wide range of sub activities related to the profession.
<b>Disclosure of relationships between Directors (in case of appointment of a Director)</b>	Not Applicable	Not Applicable

**Suraksha Diagnostic Limited**

**CIN:** L85110WB2005PLC102265

**Reg Office:** 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India

**E-mail:** investors@surakshanet.com | **Website:** www.surakshanet.com

**Phone:**(033) 6605 9750